‘Groundbreaking' drug could slow down progression of type 1 diabetes
With type 1 diabetes, the immune system attacks insulin-producing cells in the pancreas, meaning blood sugar levels are no longer regulated by the body.
If blood sugar is too high or low, it can cause serious health problems and even death.
People with type 1 therefore need daily insulin.
Dentist and mother-of-two, Hannah Robinson, from Devon, is the first adult in the UK to try the drug in the hope it can delay the condition.
She is having treatment at the Royal Devon University Healthcare NHS Foundation Trust after discovering during pregnancy she was in the early stages of developing type 1.
A handful of people are being given the medicine on a case-by-case basis while it is reviewed for wider use on the NHS.
The 36-year-old said: 'For me, this new drug offers more freedom and the chance to focus on my health before I have to start thinking differently and managing life as somebody needing daily insulin.
'This isn't just about what I eat or monitoring my glucose, it is also about having more control and not feeling defined by my condition.
'This treatment could potentially pave the way for a future cure for type 1 diabetes, which is incredible. I feel very lucky to be part of this.'
The new drug teplizumab must be given at the earliest stage of the disease to be effective.
Dr Nick Thomas, diabetes consultant and academic clinical lecturer at the University of Exeter, said: 'This new treatment represents a really exciting shift in how we manage type 1 diabetes.
'For the first time ever, we will be able to provide targeted treatment early enough in the process to alter the underlying immune process, aiming to slow down how quickly people need insulin.
'Approximately half of all type 1 diabetes cases develop in adulthood, and Hannah will be the first adult in the UK to receive this treatment.
'My hope is that in the future, we may be able to stop people with early type 1 diabetes from needing insulin at all.'
Experts at the Royal Devon and the University of Exeter are using genetics and other testing to spot people at high risk of developing type 1 diabetes.
The hope is more people could be offered the drug to delay type 1.
Dr Lucy Chambers, head of research impact and communications at Diabetes UK, said: 'For people in the early stages of type 1 diabetes, teplizumab offers a groundbreaking opportunity to buy them precious extra years insulin-free.
'Right now, it's only available in research settings – and while the excitement is real, urgent work is still needed to ensure it reaches everyone who could benefit.
'That means securing a UK licence for teplizumab, establishing national screening programmes to identify people with early-stage type 1 diabetes before symptoms appear, and preparing the NHS to deliver this treatment at scale.
'Diabetes UK is proud to be at the forefront of these efforts – funding pioneering research and working closely with the NHS towards a future where immunotherapies become the first-line treatment for tackling the autoimmune attack at the root of type 1 diabetes.'
Professor Richard Oram, consultant physician at the Royal Devon and professor at the University of Exeter, said: 'Excitingly, teplizumab is the first drug with the potential to delay type 1 diabetes, but needs to be given before clinical diagnosis due to high blood glucose.
'It is really important to find new and improved approaches for identifying individuals at elevated risk.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Rhyl Journal
2 minutes ago
- Rhyl Journal
Graduate overcomes life-changing injuries to fulfil dream of becoming a doctor
Paul Edwards was 17 and studying for his A-levels when he was knocked off his motorbike, suffering multiple fractures. He had to put his studies on hold and delayed his university ambitions for a decade while he recovered. Fast-forward 16 years and, despite living with debilitating pain, Mr Edwards, now aged 32, has graduated in front of his proud parents Charlie and Denise, girlfriend Aesha, close friends and tutors. It was not just his injuries he needed to overcome, as Mr Edwards grew up in Lawrence Weston where only around 15% of students at his secondary achieved five GCSEs. Encouraged by his parents and supportive teachers, he set his sights on studying medicine at the University of Bristol. Prior to his accident he was accepted on to the now obsolete Government-run gifted and talented programme, which sought to help talented students from disadvantaged backgrounds. But in October 2009 a car overran a junction and Mr Edwards collided with the car at 30mph. He suffered catastrophic injuries, including two fractured thighs, multiple fractures to his neck and back, a lacerated liver and head trauma. Mr Edwards spent years in recovery, undergoing multiple surgeries and battling constant pain. In 2014, he had what he calls his 'sink or swim' moment, and with the help of his GP weaned himself off opioid medication. 'I remember my GP saying: 'You can either stay on these drugs and be stuck here, or come off them and find out what life might still offer you',' he said. He enrolled in an access to higher education course and completed the equivalent of three A-levels in nine months. In 2017, Mr Edwards was offered a place to study neuroscience at Bristol, but switched to medicine during the Covid-19 pandemic. 'My sister is a paramedic, and my GP and consultants were so amazingly supportive during my recovery from my accident. I realised I wanted to help. I wanted to give back,' he said. He studied while managing with 'endless and debilitating' pain as a consequence of his injuries. 'I use over-the counter painkillers to treat the pain and I do lots of activity including endurance running and triathlons,' he said. 'I know I'll be in pain anyway, but I would rather be active and in pain, than sedentary and still in pain.' He has recently completed his elective period of study in anaesthetics and will soon begin his foundation doctor training at an NHS hospital on the Isle of Wight. 'I owe the university a lot regarding my success,' Mr Edwards said. 'I have been incredibly well supported, and I really appreciate everything the staff have done for me. 'They really help you achieve the absolute best you can be. I count myself lucky to have met so many wonderful people along the way, who are now absolute friends for life. 'Who knows, maybe the accident was part of a bigger plan – directing me to a path of becoming a doctor> 'I want to let people know that anything is possible if you are determined enough. It's never too late, and Bristol is a great place to be.'
Glasgow Times
3 minutes ago
- Glasgow Times
Graduate overcomes life-changing injuries to fulfil dream of becoming a doctor
Paul Edwards was 17 and studying for his A-levels when he was knocked off his motorbike, suffering multiple fractures. He had to put his studies on hold and delayed his university ambitions for a decade while he recovered. Paul Edwards with his parents Charlie and Denise after graduating from the University of Bristol (Nim Jethwa/University of Bristol/PA) Fast-forward 16 years and, despite living with debilitating pain, Mr Edwards, now aged 32, has graduated in front of his proud parents Charlie and Denise, girlfriend Aesha, close friends and tutors. It was not just his injuries he needed to overcome, as Mr Edwards grew up in Lawrence Weston where only around 15% of students at his secondary achieved five GCSEs. Encouraged by his parents and supportive teachers, he set his sights on studying medicine at the University of Bristol. Prior to his accident he was accepted on to the now obsolete Government-run gifted and talented programme, which sought to help talented students from disadvantaged backgrounds. But in October 2009 a car overran a junction and Mr Edwards collided with the car at 30mph. He suffered catastrophic injuries, including two fractured thighs, multiple fractures to his neck and back, a lacerated liver and head trauma. Paul Edwards (far left) completing the 2025 Bristol 10k with his father, Charlie Edwards, and sister (Paul Edwards/PA) Mr Edwards spent years in recovery, undergoing multiple surgeries and battling constant pain. In 2014, he had what he calls his 'sink or swim' moment, and with the help of his GP weaned himself off opioid medication. 'I remember my GP saying: 'You can either stay on these drugs and be stuck here, or come off them and find out what life might still offer you',' he said. He enrolled in an access to higher education course and completed the equivalent of three A-levels in nine months. In 2017, Mr Edwards was offered a place to study neuroscience at Bristol, but switched to medicine during the Covid-19 pandemic. 'My sister is a paramedic, and my GP and consultants were so amazingly supportive during my recovery from my accident. I realised I wanted to help. I wanted to give back,' he said. He studied while managing with 'endless and debilitating' pain as a consequence of his injuries. 'I use over-the counter painkillers to treat the pain and I do lots of activity including endurance running and triathlons,' he said. 'I know I'll be in pain anyway, but I would rather be active and in pain, than sedentary and still in pain.' Paul Edwards aged 17 in hospital following his accident (Charlie Edwards/PA) He has recently completed his elective period of study in anaesthetics and will soon begin his foundation doctor training at an NHS hospital on the Isle of Wight. 'I owe the university a lot regarding my success,' Mr Edwards said. 'I have been incredibly well supported, and I really appreciate everything the staff have done for me. 'They really help you achieve the absolute best you can be. I count myself lucky to have met so many wonderful people along the way, who are now absolute friends for life. 'Who knows, maybe the accident was part of a bigger plan – directing me to a path of becoming a doctor> 'I want to let people know that anything is possible if you are determined enough. It's never too late, and Bristol is a great place to be.'
South Wales Guardian
an hour ago
- South Wales Guardian
Watchdog bans host of ads for prescription-only weight-loss medications
The Advertising Standards Authority (ASA) said the nine rulings against the ads – one featuring reality TV personality Gemma Collins – made it 'crystal clear' that all injectable forms of weight-loss medication were prescription-only and therefore could not advertised to the public. In December, the ASA warned businesses and individuals who were targeting members of the public with ads for the medicines. It said no-one operating in the industry could say they had not been warned that weight-loss prescription-only medicines 'must not be promoted to the public'. The ads banned this week include an Instagram post by Collins, posted on January 6, which promoted the weight-loss service Yazen. In a video, Collins stated: 'I'm starting this year two sizes down, thanks to Yazen's weight loss app and medication. It's really quick and easy to get started with Yazen, it has absolutely changed my life… I finally found something that actually I lose weight on.' She continued: 'Yes, there's, you know, reports and stuff. And I'm not telling anyone to go on this medication, but it is prescribed on the NHS.' Two complainants challenged whether the ad breached rules because it promoted prescription-only medication to the public. Yazen said the post had been intended to share information about their 'holistic, responsible approach to weight loss', and had not been intended to focus solely on medication. Following notification of the complaint, and in agreement with Collins, the post has been amended to remove any reference to prescription-only medications. Yazen said they would ensure that future posts were compliant with the advertising code. Collins said she took her responsibilities under the advertising code seriously and strove to comply with them. She accepted that her posts had promoted the Yazen weight-loss service and app, and said Yazen would approve any marketing materials she might post in future, and she would follow any guidance that the ASA provided. The ASA also banned an ad for prescription-only weight-loss medication posted by CheqUp, which read: 'No GP or pharmacy visit, just a 2 minute online consultation.' CheqUp told the ASA that they believed the ad had been created in line with what had become widespread industry practice in the weight-loss sector. They assured the ASA that the ad would not appear again. Other providers who have had their ads banned include Juniper UK, Cloud Pharmacy, and Phlo Clinic and SemaPen. The ASA said the rulings established the advertising of named weight-loss drugs such as Wegovy, Mounjaro, Ozempic and Saxenda was banned, as was the use of various claims such as 'obesity treatment jab' and 'weight loss pen'. In April, the ASA said a search in January found around 1,800 unique paid-for weight-loss ads which were identified as potentially advertising a prescription-only medicine. It has published a joint Enforcement Notice with the Medicines and Healthcare products Regulatory Agency and General Pharmaceutical Council, making clear that ads for named weight-loss prescription-only medications are prohibited, including online, on social media and by influencers.
